🎁 Black Friday: up to 50% off of annual plans
Protagonist Therapeutics, Inc. (PTGX)
NASDAQ: PTGX · Real-Time Price · USD
121.40
-2.62 (-2.11%)
Nov 20, 2026, 4:00 PM EST - Market closed
← View all transcripts

Jefferies Global Healthcare Conference

Nov 17, 2026

Summary

ICOTYDE’s launch surpassed 20,000 prescriptions, while MIMRYLO has broad PV positioning and NCCN Category 1 guidance. Pipeline priorities include oral IL-17 and obesity peptides, with 2027 development decisions and potential partnerships ahead.

Roger Song
Senior Analyst, Jefferies

All right. Welcome, everyone, to Jefferies 2026 Global Healthcare Conference in London. My name is Roger Song, senior analyst, covers biotech in the U.S. It is my pleasure to have the fireside chat with our next company, Protagonist Therapeutics, and we have the CEO, Dinesh Patel. Welcome, Dinesh.

Dinesh Patel
CEO, Protagonist Therapeutics

Always a pleasure to be here and to have a conversation with you, Roger.

Roger Song
Senior Analyst, Jefferies

Excellent. All right, why don't you just start with the brief overview of Protagonist, which is in a very enviable position right now. So give us a minute or two.

Dinesh Patel
CEO, Protagonist Therapeutics

Yeah, I mean, it has been a long journey, but finally we have arrived at a very good place, a very unique place. At one end, we kind of are a company with two approved drugs, so we have entered into the, quote-unquote, "commercial space," but without hiring a single sales force person. That is by virtue of the two amazing partnerships that we did, the right kind of partnership at the right time, one with J&J, the other with Takeda.

Now, of course, the benefit of all that is you are validated, you and the team have this amazing satisfaction at the core level of having contributed two drugs that will make a difference in the life of patients, and you also get a very steady stream of revenue, which then in turn allows you to fund your own R&D engine without bad news for the bankers, going out and trying to raise money. On top of that, we believe the flow of money will be of such magnitude that from time to time, we should also be able to do share buybacks. So, it is like compressing a lot in a single company, but I think these are all positives, and we believe this is just the beginning.

The mastery that we have over the peptide technology platform is going to enable us to do wonderful things, as is reflected by our very thriving R&D pipeline.

Roger Song
Senior Analyst, Jefferies

Excellent. Okay. Then, as you said, you have two commercial products through two major pharma partners, and then everyone very focused on ICOTYDE, and then MIMRYLO also launching out pretty nicely. So for ICOTYDE, J&J is on the driver's seat, and then how much you can say about the revenue and then royalty trending, and then when, if you will break up, then maybe next year?

Dinesh Patel
CEO, Protagonist Therapeutics

Yeah. So, I mean, clearly, ICOTYDE has gotten a very high level of visibility, and maybe rightfully so. As you know, it also got nominated as one of the best innovative medicines by TIME magazine.

Roger Song
Senior Analyst, Jefferies

I saw that

Dinesh Patel
CEO, Protagonist Therapeutics

which is very satisfying for the scientific souls. Commercially, I mean, if you just look at the qualitative statements from J&J executives, right? I mean, the launch is almost at an unprecedented scale of more than 20,000 prescriptions already, as reported by J&J during their earnings call. Also a very nice distribution of 60% are systemic- naive, but 20% are switching from orals, and this is for psoriasis, obviously, and the other 20% are switching from injectables.

Roger Song
Senior Analyst, Jefferies

Yeah.

Dinesh Patel
CEO, Protagonist Therapeutics

This is a great beginning. Now, in terms of the precision of revenues and all that, we will follow J&J's lead. We don't want to outrun them, and I believe during their earnings call, they guided towards breaking it down as a line item sometime in 2027.

Roger Song
Senior Analyst, Jefferies

Okay. Mm-hmm. Yeah, got it. Before that, I'm going to keep using my estimate.

Dinesh Patel
CEO, Protagonist Therapeutics

Fair enough.

Roger Song
Senior Analyst, Jefferies

Yes. Yeah.

Dinesh Patel
CEO, Protagonist Therapeutics

I mean, we do have a good chunk of over $500 million of milestones also that are pending, and in theory, we believe all of those could be achievable because the development milestones are geared towards second and third indications, NDA filings and approval, and the sales milestones, we don't believe the highest hurdle is if it crosses over a $5 billion mark in a given year.

Roger Song
Senior Analyst, Jefferies

Mm-hmm. Got it. Okay, great. Obviously, they keep expanding the indication into PsA. We just saw the data at the ACR, and then also the UC and the CD, which is also a big indication for IL-23. Another thing, the field is definitely moving towards the oral peptide. You're leading that, and then J&J is also benefit from there. How do you think about, we see recent deal related to the long-acting oral peptide. So one is, how you think about that approach, compared to based on what your expertise in this field? And two is Protagonist having some capacity or the capability to do something like that, longer-acting oral peptide?

Dinesh Patel
CEO, Protagonist Therapeutics

Yeah, I think maybe I will answer the second question first. It is like, we certainly have the capability of designing longer-acting oral peptides. What is probably unclear is, what is the true differentiation value that could be derived from, let us say, a once-daily oral pill versus a once- weekly. Once- weekly is kind of uncharted territory.

Roger Song
Senior Analyst, Jefferies

Yeah.

Dinesh Patel
CEO, Protagonist Therapeutics

Scientifically, we certainly can do that. At Protagonist, at least, we derive a big differentiation between what is it that we can do versus what is it that we truly choose to do.

Roger Song
Senior Analyst, Jefferies

Yeah.

Dinesh Patel
CEO, Protagonist Therapeutics

Differentiation is key at any given time. I will leave it at that. Now, in terms of the other indications, as you well know, IL-23 injectable antibodies, that is such an amazing precedence, right? The three main antibodies, STELARA, TREMFYA, SKYRIZI, they have found 100% success in all four indications, psoriasis, psoriatic arthritis, UC, and Crohn's. We feel very confident about the outcome. Psoriasis, it is already approved. Psoriatic arthritis, the primary endpoints were met. The data was very impressive. If you look at the absolute ACR numbers, I mean, ours is an oral pill, but it matches the numbers of SKYRIZI and TREMFYA. Then UC, the phase II data, I believe, was outstanding. 30% clinical remission, that is about as high as it gets, right? Of course, logically, there is a lot of confidence in these future indications.

The other thing I will add is, I mean, if you listen to J&J, they are repeatedly saying that all this clinical development with icotrokinra is enrolling at an unprecedented pace. For example, UC is a good example, right? Just about 10, 15 days ago on ClinicalTrials.gov, it is reported that the enrollment is complete.

Which, according to my back-of-the-envelope math, that is

Roger Song
Senior Analyst, Jefferies

Very fast.

Dinesh Patel
CEO, Protagonist Therapeutics

9-12 months ahead of schedule.

Roger Song
Senior Analyst, Jefferies

Yeah, that's right.

Dinesh Patel
CEO, Protagonist Therapeutics

That's wonderful.

Roger Song
Senior Analyst, Jefferies

Mm-hmm. Yeah. Got it. Just a quick follow-up on this long-acting, the IL-23. Given your partnership, it's a great partnership with J&J. Will this, whatever you do additional for the IL-23, will be mostly with J&J or something you can do that independently, maybe sign a different partnership with J&J?

Dinesh Patel
CEO, Protagonist Therapeutics

Yeah. As you know, and you have been following us over several years now, the J&J partnership, that was inked all the way back in 2017 when it was a preclinical program.

It has continued till today. Until icotrokinra got fully secured going into phase III, the research component was still going on. You can imagine the two companies have been doing cumulative research all the way back from 2017.

It all falls under the broad category of joint research, joint collaboration, joint ownership kind of thing.

We believe that, yeah, that is a good place to be at, whether with J&J or independently.

Roger Song
Senior Analyst, Jefferies

Okay. Awesome. All right. The MIMRYLO, I think Takeda also said this is going to be a very important launch for them, maybe one of the three major products. By the way, J&J say the ICOTYDE will be the largest pharmaceutical product. I have to emphasize that.

Dinesh Patel
CEO, Protagonist Therapeutics

I'm glad you are stating it rather than me.

Roger Song
Senior Analyst, Jefferies

No, it is J&J, not me. I just repeat that.

Dinesh Patel
CEO, Protagonist Therapeutics

Right.

Roger Song
Senior Analyst, Jefferies

We also look at the historical, all the sales, the big franchise for J&J, it is up to $15 billion-$20 billion revenue. For MIMRYLO, Takeda also put a lot of the effort behind. How do you think about, because it is a rare disease compared to the psoriasis and the IL-23. How do you think about the launch trajectory? Not for you to comment on that, but just looking at the epidemiology, what is your expectation looking at the MIMRYLO?

Dinesh Patel
CEO, Protagonist Therapeutics

I think there are a number of things that come into play. I mean, if you look at MIMRYLO, it is a hepcidin functional mimetic, and it is the first of its kind. At the core level of polycythemia vera as a disease is about excessive erythrocytosis. These patients have high hematocrit. This is the first and only drug that precisely addresses just that.

Because if you look at the current treatment paradigm, it kind of doesn't discriminate between RBCs versus, let us say, platelets or white blood cells. What we found is that uncontrolled hematocrit is an issue that prevails in all kind of patients, low- risk, high- risk, people with early disease onset, late-stage disease, that sort of thing. The utility should be throughout the spectrum, so to speak, which is huge. As you know, the label has been incredibly clean. No cancer carcinogenicity issues. If at all anything, it is a broad label, and this is the first time ever that a drug in the PV space has formally a symptom improvement component in the label, the fatigue thing.

And of course, last but not least, we have been smart enough to not commercialize it on our own, but join a very capable company like Takeda and let them do the job. I think the stars are incredibly well aligned. Last but not least, NCCN, they recently gave up the guideline of putting this MIMRYLO in the Category 1, both for low-risk and high-risk population.

I would like to believe we are off to a wonderful start, and we would leave it up to our pharma colleagues to report the things in a proper way from time to time. Now, coincidentally, as you know, J&J is having their Investor Day on December 8.

Takeda is having their Capital Markets Day on December 11.

Roger Song
Senior Analyst, Jefferies

Okay.

Dinesh Patel
CEO, Protagonist Therapeutics

Japan time, so.

Roger Song
Senior Analyst, Jefferies

Okay. Got it. We are going to stay tuned on that. I have to say PV, polycythemia vera, getting a lot of attention, a lot more attention than the past year, particularly before the MIMRYLO approval and the phase III data. Now, we recently saw Merck and then Shattuck deal, $1 billion+ . You definitely get some more activity in this field. How do you think about those kind of longer-acting, maybe target a similar target, but it is more endogenous? I believe you have an oral hepcidin as well. Is that the answer for the future, the competitor? What is the feedback you are getting? I believe that is your fully owned.

Dinesh Patel
CEO, Protagonist Therapeutics

Correct. Correct.

Roger Song
Senior Analyst, Jefferies

Takeda has some.

Dinesh Patel
CEO, Protagonist Therapeutics

Whether it is with icotrokinra, there are quite a few oral IL-23s that are being developed by other companies, or whether you look at MIMRYLO, there would be longer-acting injectables, that kind of thing. In both instances, our drugs are significantly ahead of everyone else. We are going to enjoy that solo time, being the only sole presence, that kind of thing. MIMRYLO, if you think about it is like at least four, if not five years ahead of everything and anything. Look, that is part of it. It is just a natural outcome of success, and the natural progression is like, yes, there will be other drugs that will be created that may have one sort of claimed advantage or the other. Time will tell.

But if you think about it, what we have done in MIMRYLO is like we introduced MIMRYLO as a once-weekly injectable, and it's a rare disease indication. It's self-administered, so we believe it is very convenient. The next inflection point, according to us, and as you know, we are kind of focused quite a bit on oral drugs, so to speak, right? So, the second act over here is an oral hepcidin functional mimetic, and we believe that will have a very good appeal, very good differentiation. We don't see any overlap or conflict with MIMRYLO. MIMRYLO is already approved. Our oral candidate is still preclinical. It goes into clinic next year, that sort of thing. So, I think things are well balanced and well laid out.

Roger Song
Senior Analyst, Jefferies

Mm-hmm. Okay, great. So we have 10 more minutes. I do want to talk about your two major emerging pipeline based on your oral peptide platform. One is IL-17, and then the other one is the triple G. I just came back from the ObesityWeek. Definitely want to talk about that. So, for the IL-17, you reported very impressive, the healthy volunteer data, and then that trigger you to do a full-blown dose-ranging study in the very heavy investment. So, speaks to your confidence. Then, I think you said you will have some data or interim analysis next year, and then decide which direction the next step. So, tell us about the mechanism and then what exactly you're going to see mid-year next year.

Dinesh Patel
CEO, Protagonist Therapeutics

Yeah, no, look, I think that's a great topic, and in a way, we encourage people saying, "Look, I mean, ICOTYDE has been an amazing success. MIMRYLO is also going to follow a similar path." But now, as far as the future is concerned, it's our R&D pipeline, right? PN-881, the oral IL-17 blocker, is the lead over there. Our vision is really to revolutionize the whole IL-17 space, which is dominated by injectable blockbuster antibody drugs. So, if you can create an oral IL-23, why can't you create an oral IL-17?

And why can't you create an oral IL-4 down the road? But getting back to the IL-17, so 881- We really loved the phase I data that we generated. We shared a little bit of it with you folks.

Most likely, we will share more details at a medical conference next year, maybe in the first half of next year. The data is, the drug levels we saw in the healthy volunteers gave us all the conviction to move forward with a very comprehensive phase II study in psoriasis, and we have sketched out the study detail in our corporate deck as well. The idea would be to then extract a dosing regimen through which we can directly go into a phase III study.

The other thing we are going to do is, if your drug is working in psoriasis, then the response rates are high, expected to be high. Even studying at the blinded data, you should be able to make a judgment call. By the way, if your drug is not working, you will definitely be able to tell it is not working.

Roger Song
Senior Analyst, Jefferies

Okay

Dinesh Patel
CEO, Protagonist Therapeutics

studying the blinded data, right? The point is, we are not going to wait for the phase II study to be completed. We will just, in the second half of next year, assuming the enrollment is going at a decent pace, make a judgment call on the second indication. That is something we should be able to share.

Roger Song
Senior Analyst, Jefferies

Got it. Oh, you say, would you be able to share some blinded data, or just your decision to move into the next?

Dinesh Patel
CEO, Protagonist Therapeutics

Just the decision.

Roger Song
Senior Analyst, Jefferies

Okay, got it.

Dinesh Patel
CEO, Protagonist Therapeutics

Just a teaser.

Roger Song
Senior Analyst, Jefferies

Yeah, got it. Which indication is on the top of your mind?

Dinesh Patel
CEO, Protagonist Therapeutics

That is largely undecided, but maybe psoriatic arthritis will be a good choice. HS has more uncertainties, and recently it has surprised many companies in an unpleasant way through high placebo rates and that sort of thing. It is a bit complex. Maybe we should get more familiar with our drug and its performance before we dive into HS. That is the current thinking. We may change our mind. Then with regard to the triple G, PN-477-

Roger Song
Senior Analyst, Jefferies

Yeah

Dinesh Patel
CEO, Protagonist Therapeutics

we did a single- ascending- dose study, single- dose study in healthy volunteers, and we really liked the data that we saw. I mean, we saw a nice PK/PD dose- response. We saw clinical activity as well. Based on that, we basically said, and remember I mentioned early on that we are always about differentiation. Then it is like with sub-Q, we got the, quote- unquote, "proof" or that evidence of clinical activity that we were looking for, and that was good enough. It served the purpose. We do not see much value at this stage in developing a triple sub-Q on our own when retatrutide is already showing great data, hats off to Eli Lilly, in a phase III study. So, our focus is on the oral, the oral triple. That has become the high priority right now.

And in a way, what we are doing in obesity is like now it is just a, we are creating a portfolio with oral peptide drugs, the oral triple, the oral dual is maybe six months behind it, and then also, we are working on oral amylin, although it is a bit early.

Roger Song
Senior Analyst, Jefferies

Mm-hmm. Okay, got it. One comment you have is for the sub-Q, you say retatrutide level activity at a much lower dose. And then, now you are focused on the oral side. How we think about the oral potency and exposure level compared to your sub-Q?

Dinesh Patel
CEO, Protagonist Therapeutics

Another great question. Here, pre-clinically also, we made observations that if you do equal milligram dosing of, let's say, retatrutide versus PN-477, we were seeing observable better weight loss, or higher weight loss with our drug. In phase I, what we saw, now these are cross-trial comparisons, so one has to take it with a grain of salt, but for retatrutide, single- dose data is out there. When we compare it with our data, what we find is that whatever effect retatrutide created at a particular dose, our drug will do it at 4x-5x lower dose.

Then loosely it is translating to maybe higher potency, but I think it will have very positive implications, as you can imagine, right? I mean, now when we go into the oral study, the burden on oral bioavailability or how much material you need, that is going to be lower by 4x-5x , which could be very significant.

Roger Song
Senior Analyst, Jefferies

Mm-hmm. Got it. Yeah. So what will be the TPP for your oral? Because your icotrokinra is injectable level efficacy, and then the tolerability even better, and we can say that. Then for the IL-17, probably you are targeting the similar level. Then for the oral peptide, oral triple G, the relative is very good activity, and then the tolerability maybe can be improved. So what's your TPP for the oral?

Dinesh Patel
CEO, Protagonist Therapeutics

Yeah, in most of these instances, I mean, you're able to do titration to effect, for example. Using obesity as an example, it will all depend on how much weight loss is desirable in a particular patient, and then the dosing can be titrated to effect, so to speak. But in broad strokes, with the oral, what we would expect is like you have to be in the ZIP code of the injectables. You don't have to exactly match it. Our advantage is, hey, we are oral, so we can afford to have a little bit of haircut in terms of the efficacy or potency.

Roger Song
Senior Analyst, Jefferies

Got it. One of the key aspects of the oral is the bioavailability. I know you have a discovery platform for the oral peptide developing very potent drug. How about the formulation and the bioavailability? What is the bioavailability you have for the oral triple G to ensure the exposure level?

Dinesh Patel
CEO, Protagonist Therapeutics

Yeah, I think the first step should be like, as much as possible, you should try to design your peptide in such a way that it has inherent bias towards better bioavailability. If you think about it, for icotrokinra, for example, there is no formulation assistance, right? Yet its performance is amazing. So what we strive for is like amazing potency, which by the way also translates to very high level of specificity, a big advantage over small molecules, right? That kind of lowers the burden of bioavailability. But yeah, you can enhance the bioavailability through specific formulations. Obviously, we are kind of taking advantage of that as well. But it is a balancing act of the core potency, the core bioavailability of your peptide, and enhancing it a little bit through formulation, and of course, fine-tuning the half-life.

Once the drug is in the bloodstream, then it hangs around to get the job done.

Roger Song
Senior Analyst, Jefferies

Got it. Okay. Just lastly, you had two very successful partnership. One is very early on research stage, the other one is near phase III data, and also mostly the commercial. Now you have two new kids, so to speak.

Dinesh Patel
CEO, Protagonist Therapeutics

That's right. It's a growing family.

Roger Song
Senior Analyst, Jefferies

Yeah. Then the I&I and then the obesity. Admittedly, I think obesity probably more involved on the capital side. How do you think about the partnering strategy for your two?

Dinesh Patel
CEO, Protagonist Therapeutics

I think it's a fantastic question. In the obesity space, we have no illusions of doing phase III studies on our own. It's really a portfolio that will benefit from a partnership. With the oral IL-17, we are already on our way towards a phase II with psoriasis. We will take on other indications. But I think at the right junction, maybe before we go into phase III, that could be one inflection point where a partnership could do a wonderful job. Just by doing a partnership, we don't have to give it up. Now we have the financial strength to participate in co-development, clinical co-development, and those sort of things, right? So the idea will be to retain better economics and do deals that will be valued and accepted by the shareholders.

Roger Song
Senior Analyst, Jefferies

Mm-hmm. By the way, your Takeda partnership is amazing economics for you in the later stage.

Dinesh Patel
CEO, Protagonist Therapeutics

I jokingly tell people it is like, MIMRYLO is like, okay, and it is a rare disease drug, as you know, so it is like we have a bigger portion of a small pie. With icotrokinra, it is a much bigger pie, so we may have a smaller portion of a much bigger pie. The numbers will do their talking.

Roger Song
Senior Analyst, Jefferies

Yeah. Okay. Great. Thank you so much, Dinesh, and thank you, everyone. Thank you.

Dinesh Patel
CEO, Protagonist Therapeutics

Thank you.